ASCO-2011 – RG7204 Vs Ipilimumab : The first line Dilemma persists
ROG and BMY announced the detailed data from phase III pivotal studies on RG7204 and ipilimumab respectively. With the overall survival data on the two drugs more or less comparable, physician is likely to weigh ipilimumab’s superior durability of response compared to RG7204 (19.3m vs 6.7m) on one side with its inferior toxicity profile (56% vs 10% ≤ Grade 3 safety events) on the other side for deciding on the first line treatment option. Emergence of biomarkers for predicting ipilimumab response would be crucial for resolving this dilemma. Retrospective analysis of clinical trials shows the absolute lymphocyte count is a strong proxy for predicting durability of response with ipilimumab.
COMPANIES MENTIONED
Roche, Bristol Myers Squibb, Daiichi Sankyo, ROG, BMY, 4568
Roche, Bristol Myers Squibb, Daiichi Sankyo, ROG, BMY, 4568
